UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

VOLUNTARY ANNOUNCEMENT — INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This announcement is made by Uni-Bio Science Group Limited ("**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest developments of the Group.

Pursuant to a resolution of the shareholders of the Company passed at the annual general meeting held on 16 May 2024, the directors ("**Directors**") of the Company were given a general mandate ("**Repurchase Mandate**") to exercise all powers of the Company to repurchase shares ("**Shares**") of the Company with the aggregate number of Shares to be repurchased by the Company up to 616,358,814 Shares, being 10% of the total number of issued Shares as at the date of the meeting, with such mandate to expire upon whichever is the earliest of: (a) the conclusion of the next annual general meeting of the Company; (b) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company, the Companies Act or any other applicable law of the Cayman Islands to be held; or (c) the date on which such mandate granted under the resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.

The board ("**Board**") of Directors wishes to announce that it has an intention to exercise its powers under the Repurchase Mandate and the Board has decided to utilise the Repurchase Mandate, with an intention to repurchase Shares in the open market from time to time up to an aggregate amount of HK$15 million ("**Proposed Share Repurchase**") commencing from 29 August 2024 to 31 December 2024.

The Board considers that the current trading price of the Shares does not adequately reflect the Company's intrinsic value and the actual business prospects of the Group. As highlighted in the interim results announcement of the Company for the six months ended 30 June 2024 indicated a strong growth of bottom line and positive cash flow, with the fundamental business expected to be recurring and growing in the mid-term. The Board believes that the Proposed Share Repurchase demonstrates the confidence of the Board in the long-term strategy and growth of the Company, and the Proposed Share Repurchase would benefit the Company and create value to its shareholders as a whole. The Proposed Share Repurchase shall not result in the number of the Shares held by the public falling below the relevant minimum percentage prescribed by the Listing Rules. The Board believes that the current financial resources of the Company would enable it to implement the Proposed Share Repurchase while maintaining a solid financial position.

The Company will conduct the Proposed Share Repurchase in compliance with the articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Act of the Cayman Islands and all applicable laws and regulations. The Company will finance the Proposed Share Repurchase with its internal resources.

Shareholders and potential investors of the Company should note that any repurchase may be done subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase. Shareholders and potential investors of the Company should therefore exercise caution when dealing in the securities of the Company.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 28 August 2024

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman) and Mr. Zhao Zhi Gang; one non-executive Director, Mr. Yau Kwok Wing Tony; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.